Pfizer tracks safety of cancer drug in small patient group
NCT ID NCT06735742
Summary
This study is monitoring the safety of the drug Talzenna in a small group of patients with advanced breast cancer that has returned or cannot be surgically removed. The patients have a specific genetic profile and have received prior chemotherapy. The main goal is to track any side effects that occur while patients take the drug for up to one year.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer Japan
Tokyo, Japan
Conditions
Explore the condition pages connected to this study.